Psychedelic Treatments Gaining Attention in Washington

For years now, advocates for psychedelic substances have been taking their messages to Washington, D.C. Currently, drugs like LSD and MDMA, both illegal, are under scrutiny for their potential therapeutic benefits in treating severe mental health issues such as depression and PTSD.

Borderline personality disorder (BPD) and clinical depression often share symptoms like persistent sadness and suicidal thoughts, but they’re not the same. The root causes and biological mechanisms differ significantly. Thus, traditional antidepressants tend to fall short in addressing BPD-related emotional challenges. They primarily target mood-related neurochemistry, rather than the deeper behavioral and relational issues that complicate BPD.

Other mental health conditions, like PTSD, also prove difficult to treat with standard pharmacological methods.

Yet, it seems the current presidential administration is ready to explore psychedelics as a part of mental health solutions.

Notable figures within the Trump administration, including:

• Robert F. Kennedy Jr. – Secretary of the Department of Health and Human Services
• Doug Collins – Secretary of Veterans Affairs
• Dr. Casey Means – Trump’s Candidate for U.S. Surgeon General
• FDA Commissioner Marty McCurry

Health Secretary Robert F. Kennedy Jr. expressed optimism to Congress, saying, “This series of treatments is working very hard to make sure that, given in a clinical setting, that will happen within 12 months.”

Kennedy Jr.’s timeline for possible approval surprised even the most hopeful advocates of psychedelics. This announcement comes as states like Texas begin to shift attitudes toward psychedelic use.

The backing from RFK Jr.’s office has sparked a mix of excitement and skepticism among mental health experts. Some worry that a rush to approve these treatments could mislead the public, especially given Kennedy Jr.’s controversial stances on various health issues.

Rick Doblin, who has championed MDMA’s medical use since the 1980s, expressed a blend of hope and concern: “I’m very optimistic… but I’m also worried that the message that the public might get is that ‘Well, RFK likes psychedelics and is now approved.’

Under the Biden administration, efforts to approve MDMA as a PTSD treatment stalled due to concerns about research quality. Regulators opted to pursue more thorough studies, a process that can extend over years.

Ketamine, initially an anesthetic, has gained traction for off-label use in treating various mental health issues, including treatment-resistant depression and anxiety. Its safety profile has made it a popular choice in clinical settings.

Meanwhile, efforts from FDA Commissioner Marty McCurry aim to prioritize MDMA and other psychedelics, potentially streamlining their evaluation processes and easing some regulatory hurdles.

However, established methodologies in scientific research typically remain obstacles in this field.

Recently, the U.S. Department of Health and Human Services and the FDA brought in new staff closely connected to psychedelic research.

Greg Ferenstein, a fellow at the Libertarian Reason Foundation, noted, “All of these are very promising signs that the administration is aware of the potential of psychedelics and is trying to create an overture that they are ready to approve them. We didn’t hear anything about that in the Biden administration.”

Additionally, Kennedy Jr. has shared how some personal stories, including that of his son, have illuminated the benefits of psychedelics for tackling emotional issues.

Discussions regarding access to psychedelic therapy among veterans are ongoing, particularly with Secretary Collins.

Collins commented positively on the current initiatives in May, noting, “What I’ve seen so far is positive.”

As federal officials weigh the future of psychedelic treatments, some states, like Oregon and Colorado, are taking the lead to make their own legislative moves. For instance, Texas recently allocated $50 million for research into Ibogaine, a potent psychedelic from African shrubs, which could offer relief for opioid addiction and PTSD, drawing bipartisan support.

Despite its potential, Ibogaine remains classified as a Schedule I drug, similar to heroin, which complicates its path toward acceptance for medical use. Advocates in Texas are working to change this.

Brian Hubbard, part of the Ibogaine initiative, commented on systemic delays: “The government system moves slowly and inefficiently. Sometimes they are constrained in terms of progress that can be made from within.”

Ibogaine is unique in its combination of potential benefits and safety concerns. While limited research hints at its effectiveness, it has also been tied to serious side effects. It enjoyed medical use in France for decades, until safety concerns arose.

Marcus Capone, a Navy SEAL, shared his personal experience after trying Ibogaine: “I then felt my weight was completely off my shoulders. There’s no more anxiety or depression, and life suddenly makes sense.”

Capone’s organization, which supports veterans, has facilitated over 1,000 veterans in accessing ibogaine and other psychedelic treatments abroad.

While there were federal inquiries into ibogaine, they were halted due to health concerns raised a few years back. NIDA’s director Nora Volkow reflected on the challenges ahead for FDA approval in psychedelic medicine, stating, “I’m going to die underwater.”

Yet, Volkow has expressed ongoing interest in the potential of psychedelics, including Ibogaine, and the development of safer, synthetic versions of these substances for research.

“I’m very interested in their pharmacological properties and how they affect their brains,” she added, cautioning against hype while ensuring a rigorous evaluation process.